Cellromax Science Co., Ltd.

As of June 30, 2026, Cellromax Science Co., Ltd. carries a market capitalization of 48.92B, placing it among publicly traded companies globally. Its enterprise value stands at 39.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Cellromax Science Co., Ltd. has 10.99M shares outstanding.

As of June 30, 2026, Cellromax Science Co., Ltd. trades at a trailing price-to-earnings ratio of 16.29. The price-to-sales ratio is 2.55, and the price-to-book ratio stands at 1.04.

As of June 30, 2026, Cellromax Science Co., Ltd. trades at an EV/EBITDA multiple of 15.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 39.81B versus a market cap of 48.92B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cellromax Science Co., Ltd. maintains a current ratio of 5.98, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.65, indicating moderate leverage, while an interest coverage ratio of 104.70 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cellromax Science Co., Ltd. posted a return on equity (ROE) of 6.77, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 6.21, measuring how efficiently the asset base is converted into earnings. The company generates approximately 375.20M in revenue per employee across its workforce of 52.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.11 indicates how many times Cellromax Science Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cellromax Science Co., Ltd. recorded an income tax benefit of -322.45M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 2.75B, leaving 3.07B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Cellromax Science Co., Ltd.'s stock has declined approximately 23.34% over the past 52 weeks. The 50-day moving average sits at 4,052.50, while the 200-day moving average is 4,734.65.

Over the twelve months ended June 30, 2026, Cellromax Science Co., Ltd. generated 19.60B in revenue and converted that into 3.07B in net income, yielding earnings per share of 272.60. EBITDA reached 2.60B, while operating income came in at 2.15B.

As of June 30, 2026, Cellromax Science Co., Ltd. holds 9.42B in cash and equivalents against 306.11M in total debt, resulting in a net debt position of -3.35B. Total book value stands at 46.92B, with working capital of 12.82B providing operational flexibility.

Cellromax Science Co., Ltd. produced 2.17B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -117.51M in capital expenditures, free cash flow totaled 2.06B - equivalent to 183.23 per share.

Over the twelve months ended June 30, 2026, Cellromax Science Co., Ltd. posted a gross margin of 50.06, reflecting its pricing power and cost economics. The operating margin of 10.98 and net profit margin of 15.65 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Cellromax Science Co., Ltd. paid dividends of 134.98 per share. The dividend payout ratio of 49.40 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.11, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.98, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cellromax Science Co., Ltd. shareholders.

As of June 30, 2026, Cellromax Science Co., Ltd. has an Altman Z-Score of 10.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.